ZYMERON CORPORATION
Federal contract awards won by ZYMERON CORPORATION (UEI GAMMMRQ6QMN1), 2019–2024 — public record from USAspending.
Showing awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
19
awards
$18,261,776
total value
2
agencies
Agencies buying from ZYMERON CORPORATION
What ZYMERON CORPORATION sells
Awards
DHA SBIR DIRECT PHASE II H2D-0243 RAPID SAMPLE PROCESSING DEVICE TO SUPPORT BATTLEFIELD WOUND INFECTION DIAGNOSTICS
Department of Defense · $2,999,983 · Sep 20, 2024
DHA STTR PH I PROPOSAL H23B-001-0020 ,TOPIC DHA23B-001-0020 TITLE AN AUTOMATED BLOOD-IN, MIRNAS-OUT ASSAY TO DETECT CIRCULATING AND EXOSOME MIRNAS EGS 2300543 MEDICAL R AND D
Department of Defense · $250,000 · Oct 6, 2023
DHA SBIR DIRECT TO PH II MEDICAL R&D CONTRACT AWARDED FROM PROPOSAL NO.-H2D-0119 FOR "DEVELOPMENT FOR SHOCKDEFENDER AGAINST HEMORRHAGIC SHOCK"
Department of Defense · $2,999,999 · Sep 15, 2023
ZYMERON DHA SBIR PHASE I H231-004-0023 NOVEL AEROSOL THERAPY FOR IMMEDIATE AND SUSTAINED ARDS MANAGEMENT
Department of Defense · $250,000 · Jun 30, 2023
SBIR TOPIC 441. ZYMERON WILL DEVELOP USER-FRIENDLY TECHNOLOGIES AND DEVICES TO CREATE AN AT-HOME HEPATITIS C VIRUS TEST.
Department of Health and Human Services · $400,000 · Sep 19, 2022
AUTOMATED PARTIAL OCCLUSION FOR TRUNCAL HEMORRHAGE CONTROL SBIR PHASE II AWARD
Department of Defense · $989,815 · Aug 26, 2022
AWARD OF ZYMERON'S DHA SBIR PHASE II MEDICAL R&D CONTRACT FOR "NOVEL ANTIBIOTICS TARGETING MULTIDRUG-RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS"
Department of Defense · $1,100,000 · Jul 11, 2022
POINT-OF-CARE (POC) DIAGNOSTICS FOR ANTIMICROBIAL RESISTANT (AMR) ENTERIC BACTERIAL AND PARASITIC PATHOGENS
Department of Health and Human Services · $300,000 · Jul 1, 2022
AWARD OF ZYMERON'S DHA SBIR PHASE II MEDICAL R&D CONTRACT FOR "DEVELOPMENT FOR A NOVEL COUNTERMEASURE, RADIODEFENDER, AS A RADIOPROTECTOR FOR HEMATOPOIETIC ACUTE RADIATION SYNDROME"
Department of Defense · $2,999,993 · Feb 7, 2022
ORODISPERSIBLE FILM OF SECOND LINE DRUG FOR PEDIATRIC TUBERCULOSIS TREATMENT.
Department of Health and Human Services · $300,000 · Sep 3, 2021
RAPID POINT OF CARE TESTS TO QUANTIFY HEPATITIS C VIRUS
Department of Health and Human Services · $300,000 · Aug 31, 2021
RAPID POINT OF CARE TESTS TO SIMULTANEOUSLY QUANTIFY ANTI-TB DRUGS IN BLOOD.
Department of Health and Human Services · $1,272,000 · Aug 12, 2021
THE CONTRACTOR SHALL DEVELOP A NOVEL NANOPARTICLE DELIVERY SYSTEM TO ELICIT POTENT AND LONG-LASTING ANTIBODY RESPONSE AND BROADLY NEUTRALIZING ACTIVITY AGAINST HIV.
Department of Health and Human Services · $300,000 · Jul 1, 2021
THE CONTRACTOR SHALL PROPOSE NOVEL, LOW-COST, REAL-TIME POINT-OF-CARE (POC) ASSAYS FOR HIV VIRAL LOAD MONITORING, HIV DRUG RESISTANCE MONITORING, AND PHARMACOLOGICAL ADHERENCE MONITORING.
Department of Health and Human Services · $299,988 · Jul 1, 2021
THE OBJECTIVE OF THIS CONTRACT IS TO DESIGN, SYNTHESIZE COMPOUNDS THAT BIND TO NEF, AN HIV ACCESSORY PROTEIN.
Department of Health and Human Services · $300,000 · Jul 1, 2021
MEDICAL RESEARCH AND DEVELOPMENT ARMY STTR PH II PROPOSAL NO. A2-8349 TITLED LONG LASTING DRUG IMPLANTS FOR MALARIA CHEMOPROPHYLAXIS.
Department of Defense · $1,099,999 · Feb 22, 2021
SBIR PHS 2020-1, TOPIC 084 ENTITLED "ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION"
Department of Health and Human Services · $300,000 · Aug 21, 2020
THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A NOVEL HIV VACCINE CO-DELIVERY SYSTEM: AN INJECTABLE THERMOSENSITIVE HYDROGEL ENCAPSULATING POLYROTAXANE (PRX)-BASED SARNA (PRX-SARNA) NANOPARTICLES AND CYTOKINE ADJUVANT GM-CSF FOR TARGETED DELIVERY TO A
Department of Health and Human Services · $300,000 · Jun 1, 2020
COMPLETE SBIR TOPIC 46 PHASE II TASKS
Department of Health and Human Services · $1,500,000 · Aug 1, 2019
Researching this competitor? BidCatch doesn't just show you what they won — it sends you the open bids in your trade every morning, before they're awarded. Free for 14 days, then $49.99/month.
Search open bids